Titlebook: Reverse Transcriptase Inhibitors in HIV/AIDS Therapy; Vassil St.Georgiev,Gail Skowron (Chief),Joep M. A. Book 2006 Humana Press 2006 AIDS.

FEAS

PAD416

Efavirenz,l replication in all cellular and body compartments (., .). This response seems to be associated with at least partial immune reconstitution and a marked reduction in the risk of clinical events or death. Additionally, reducing the rate of viral replication to very low levels also seems to delay the

RADE

Delavirdine,d with HIV infection. In one US study of 1255 patients in the early era of HAART, mortality declined from 29.4 per 100 person-years in the first quarter of 1995 to 8.8 per 100 person-years in the second quarter of 1997 (. . A Canadian population-based cohort study also confirmed that patients initia

allude

Resistance to Non-Nucleoside Reverse Transcriptase Inhibitors,been treated with this class of agents has grown. The three Food and Drug Administration-approved NNRTIs, efavirenz, nevirapine, and delaviridine, have been shown to be potent additions to the antiretroviral (ARV) armamentarium. In many studies, these compounds have been shown to be effective compon

antidote

gnarled

New Reverse Transcriptase Inhibitors in Development,iretroviral drug (ARV) target. Although several polymerases are found in human cells, none are comparable to HIV RT in their ability to catalyze the synthesis of new DNA from an RNA template. A selective RT inhibitor should, therefore, exert limited toxicity. The RT enzyme plays a crucial role in th

Sarcoma

Antiretroviral Drugs for Millions,ribed in 1997. However, approx 80% of individuals who are on treatment are residents of industrialized countries of the world, where fewer than 10% of the HIV-infected individuals make their home. In contrast, in December 2004, in sub-Saharan Africa, less than 300,000 individuals are taking antiretr

吞噬

Peripheral Neuropathy Associated With Nucleoside Reverse Transcriptase Inhibitor Therapy,e system to viral antigens, opportunistic processes unleashed when immune deficiency has occurred, or as adverse effects of therapies for AIDS-related diseases. To provide a context for understanding the toxic neuropathies, these other HIV-related neuropathies are briefly described in this first section.

RAFF

exigent

Nevirapine,understanding which patients might benefit and which patients might require frequent monitoring to limit toxicity. Nevirapine is a highly active antiviral compound that is used commonly in various patient populations.